DarioHealth (NASDAQ:DRIO) Upgraded to “Hold” at Wall Street Zen

DarioHealth (NASDAQ:DRIO) was upgraded by analysts at Wall Street Zen to a “hold” rating in a report released on Saturday, Wall Street Zen reports.

Several other brokerages have also weighed in on DRIO. Weiss Ratings restated a “sell (e+)” rating on shares of DarioHealth in a research note on Tuesday, October 6th. BTIG Research started coverage on DarioHealth in a research report on Tuesday, October 27th. They set a “buy” rating and a $6.00 price target on the stock. TD Cowen dropped their price objective on DarioHealth from $11.00 to $8.00 and set a “hold” rating on the stock in a report on Wednesday, August 12th. Stifel Nicolaus dropped their price objective on DarioHealth to $5.00 and set a “buy” rating on the stock in a report on Friday. Finally, Alliance Global Partners started coverage on DarioHealth in a research report on Wednesday, August 19th. They issued a “buy” rating and a $12.00 price objective for the company. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, DarioHealth has a consensus rating of “Hold” and a consensus target price of $7.75.

DarioHealth Price Performance

NASDAQ:DRIO opened at $1.26 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.31 and a quick ratio of 1.92. The firm has a market cap of $12.35 million, a price-to-earnings ratio of -0.32 and a beta of 1.18. The company has a 50 day moving average price of $5.03 and a 200-day moving average price of $7.32. DarioHealth has a 1-year low of $1.26 and a 1-year high of $14.77.

DarioHealth (NASDAQ:DRIO) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.95) by $0.22. The company had revenue of $5.31 million for the quarter, compared to analyst estimates of $5.21 million. DarioHealth had a negative net margin of 159.85% and a negative return on equity of 55.10%. Equities research analysts forecast that DarioHealth will post -2.94 EPS for the current year.

Institutional Investors Weigh In On DarioHealth

Institutional investors have recently bought and sold shares of the company. Commonwealth Equity Services LLC acquired a new position in shares of DarioHealth during the 3rd quarter worth approximately $159,000. BlackRock Inc. purchased a new stake in shares of DarioHealth in the second quarter valued at approximately $249,000. Finally, Nantahala Capital Management LLC increased its holdings in shares of DarioHealth by 60.2% in the third quarter. Nantahala Capital Management LLC now owns 978,340 shares of the company’s stock valued at $6,746,000 after purchasing an additional 367,649 shares during the last quarter. 33.39% of the stock is currently owned by institutional investors and hedge funds.

Latest DarioHealth News

These are some of the DRIO news items that stood out recently:

• Positive Sentiment: Management said contracted and late-stage annual recurring revenue totaled $13.1 million across more than 180 accounts, with over 80% tied to multi-condition opportunities. It expects revenue growth to accelerate late in 2026 and into 2027 as committed ARR converts, and cited a new New Jersey health-plan customer covering 1.5 million people. DarioHealth Q3 results
• Positive Sentiment: Stifel Nicolaus lowered its price target to $5 but maintained a Buy rating, indicating that the analyst still sees substantial potential upside from the referenced share price. Stifel Nicolaus ratings
• Neutral Sentiment: Despite the improving operating trends, DarioHealth remains loss-making, and GAAP gross margin edged down to 59% from 60% a year earlier. The forecasted growth depends on converting contracted and late-stage opportunities, so execution and the timing of revenue remain key risks. DarioHealth Q3 results

DarioHealth Company Profile

DarioHealth Corp. is a digital health company that develops technology-enabled programs to help people manage chronic and behavioral health conditions. Its offerings combine mobile applications, connected devices, coaching and personalized guidance. The company’s services address conditions including diabetes, hypertension, weight management, musculoskeletal health and behavioral health. Its platform is designed to support individuals as well as employers and health plans seeking to provide digital health programs to their members.